Formal Monod-Wyman-Changeux allosteric mechanisms have proven valuable in framing research on the mechanism of etomidate action on its major molecular targets, g-aminobutyric acid type A (GABA A ) receptors. However, the mathematical formalism of these mechanisms makes them difficult to comprehend.
INTRODUCTION
The modern era of research on general anesthetics began in the early 1980s with the paradigm-shifting work of Franks and Lieb, who critiqued the longstanding focus on unitary mechanisms and anesthetic-lipid interactions [1] and redirected the field toward proteins as anesthetic target molecules [2] . Research groups focused largely on neuronal ion channels and identified several dozen target candidates, based on the broad criteria of physiological plausibility plus sensitivity to clinically relevant anesthetic concentrations. From this work, it became apparent that the wide variety of clinical general anesthetics could be divided into several broad subclasses based on their selectivity for various neuronal ion channels [3, 4] . Some anesthetic drugs, notably etomidate and alphaxalone, were recognized as remarkably selective for anesthetic targets, acting almost exclusively at g-aminobutyric acid type A (GABA A ) receptors.
In the case of one drug, etomidate, we know the molecular targets, have identified the location of binding sites within those targets, and have developed quantitative functional models for anesthetic actions at the molecular level [5 & ]. Etomidate has provided the best evidence for the presence of anesthetic-binding sites within target protein molecules. Evidence includes enantioselectivity (stereospecificity) in animals and GABA A receptors [6] [7] [8] , and single-site mutations that dramatically alter etomidate sensitivity at both the molecular [9] and whole-organism level [10, 11] . A photosensitive derivative of etomidate, azi-etomidate, covalently modifies two amino acids on separate GABA A receptor subunits [12] . Homology models of GABA A receptors, based on high-resolution structural data from homo-pentameric ligand-gated ion channels in both bacteria [13] and invertebrate flatworms [14 && ], indicate that the photolabeled residues reside on helical transmembrane domains that abut intersubunit etomidate-binding pockets. Typical synaptic GABA A receptors contain two such etomidate-binding sites.
Although the concepts of molecular drugreceptor interactions are widely familiar, the allosteric formalism used to describe how etomidate binding to its sites affects the function of GABA A receptors is difficult to comprehend. Understanding this mechanism is important, as it serves as the hypothetical framework for interpreting the effects of GABA A receptor mutations, other chemical modifications of the receptor, and structural modifications to the etomidate molecule. Thus, the major aim of this review is to review the basic concepts underlying two-state Monod-Wyman-Changeux (MWC) allosteric models as they apply to etomidate and GABA A receptors [15] . Although these concepts have been reviewed in the past by others [16] , I provide an illustrated model for understanding MWC agonism, based on the familiar ideas of chemical free energy and equilibria. This model is used to explain the functional interactions of GABA and etomidate in wild-type GABA A receptors and the 'phenotype' of one receptor mutant.
DESCRIPTIVE ANALYSIS OF ETOMIDATE ACTIONS ON GABA A RECEPTORS
In voltage-clamp electrophysiological studies of neuronal and heterologously expressed GABA A receptors, etomidate produces several functional effects [15] . Low concentrations of etomidate, including concentrations present in brain and blood during induction of general anesthesia (1-3 mM), enhance the activation of GABA-activated GABA A receptors. For example, when using a low concentration of GABA that elicits a submaximal response, addition of low concentrations of etomidate increases the amplitude of the receptor-mediated chloride current. Response to high maximally stimulating concentrations of GABA, similar to those at synapses (1-3 mM), is only enhanced about 15-20% by etomidate. If one studies the receptor responses to a wide range of GABA concentration, addition of etomidate produces a large 'leftward shift' in the concentration-response relationship. Thus, in the presence of etomidate, GABA A receptors become more sensitive to GABA (GABA EC 50 is reduced).
In addition to enhancing GABA responses, high concentrations of etomidate (more than tenfold higher than clinically relevant concentrations) directly activate GABA A receptors. Pharmacological and mutational studies have shown that this direct activation or agonism by etomidate is not mediated by the GABA-binding sites of the receptors. However, etomidate's direct agonism of GABA A receptors and its enhancement of GABA responses display remarkable parallels. The R(þ) enantiomer of etomidate induces both of these actions 20-fold more potently than the S(À) enantiomer [7] . Both actions are produced in GABA A receptors containing b2 or b3 subunits, but not b1 [17] , and mutations from asparagine (N) to methionine (M) at position 265 in b2 or b3 eliminates both etomidate actions [9] . These observations suggest that both etomidate modulation of GABA responses and its direct agonism of GABA A receptors are mediated by the same binding sites.
On the basis of these observations, we searched for mechanisms that account for both etomidate effects via a single class of sites. We found that MWC allosteric co-agonist models quantitatively account for the functional effects of GABA or etomidate alone and in combination with each other [15] .
MONOD-WYMAN-CHANGEUX ALLOSTERISM IN A SIMPLE TWO-STATE MECHANISM
Monod, Wyman, and Changeux introduced their allosteric model in 1965 [18] , applying it to multisubunit enzymes. MWC models assume that proteins exist in a limited number of functional states, and that all subunits shift between these states in a symmetrical and coordinated manner. The simplest MWC models have only two functional states (Fig. 1a) The DDG scale is set at zero for this C : O ratio. This low level of spontaneous activity cannot be detected using macrocurrent electrophysiology methods. Panel (b) depicts a MWC allosteric model with a single GABA (G) binding site. Using our estimated efficacy value for each GABA, corresponding to 16 kJ/mol of gating energy, binding of a single GABA molecule is expected to increase P open to approximately 0.05. This prediction is remarkably consistent with results of experiments where one of the two GABA sites is altered with a bY205S mutation, dramatically reducing GABA affinity for that site [20] . 
In the case of synaptic GABA A receptors consisting of a1, b2, and g2 subunits, L 0 is estimated to be about 20 000. That is, only about 1 in 20 000 channels is spontaneously open. (Fig. 1b) , a very high concentration of GABA will bind all receptors, so that only CG and OG states exist. Shifting the equilibrium more strongly toward OG occurs if GABA binds to O more tightly than to C. We define the dissociation constant for GABA binding to closed states as K G and to open receptors as K G Ã ¼ cK G . Thus, if c less than 1, GABA is an agonist. The factor c can be understood as a determinant of GABA efficacy, influencing the ratio of open versus closed receptors as GABA binds. As a thought experiment, consider that when c ¼ 1, G binds with equal affinity to closed and open receptors, and its binding will not change the distribution of closed and open states. The cyclic constraints in the mechanism shown in Fig. 1b demand that the closed : open ratio for ligandbound receptors (CG : OG) be cL 0 . Thus, at saturating high concentrations of GABA, the channel open probability in a one-site model becomes
AGONISTS SHIFT THE TWO-STATE EQUILIBRIUM TOWARD OPEN STATES
Note that the maximum open probability depends on both c and L 0 factors. If L 0 is 20 000, then c must be smaller than 5 Â 10 À5 to result in P max greater than 0.5. However, when L 0 is small, a model feature associated with spontaneous channel activity, then c can be only modestly less than 1 and still result in efficacious channel gating. The open probability as a function of [GABA] for a single-site allosteric agonist model also includes the factor K G , which influences GABA binding to its site:
Note 
At very high [GABA], Eq. (4) becomes
À3 will result in P max greater than 0.5. This MWC mechanism was experimentally demonstrated for GABA agonism by Chang and Weiss [19] .
The MWC co-agonist model treats etomidate as an agonist that acts at sites distinct from those where GABA binds. Etomidate also acts at two equivalent sites. Thus, the action of etomidate alone is described by Eq. (5) using a binding factor K E and an efficacy factor, d:
To describe activity as a function of both [etomidate] and [GABA], the full MWC co-agonist model treats them symmetrically, with five parameters (L 0 , K G , K E , c, and d):
CO-AGONISM EXPLAINS ETOMIDATE ACTIONS AS ENERGY ADDITION
Another way to understand MWC allosterism is to consider what the cyclic scheme means in terms of binding and gating energy. Essentially, ligandbinding energy is equal to the energetic shift in the gating equilibrium. The Gibbs free energy (DG) associated with a chemical equilibrium, K eq , is
where R is the gas constant (8.314 J/K/mol) and T is absolute temperature (deg K). Figures 1-3 illustrate this concept as the balance of basal closed versus open forces (DG 0 ) and the opening energy added when agonists occupy their sites. Figure 1a shows the basal gating energetics of wild-type a1b2g2L GABA A receptors. The DDG scale is 'zeroed' to a closed : open ration (L 0 ) of 20 000. The low detection limit in typical macrocurrent electrophysiology experiments is about 0.5% of channels activated, and for wild-type GABA A receptors, we estimate that additional activation energy of about 12 kJ/mol is required to detect macrocurrents. For a1b2g2L receptors we estimated c, the efficacy factor for GABA, to be about 0.002 [15] . Using Eq. (7), we calculate that each GABA-binding event provides about 16 kJ/mol of opening energy. When two GABA molecules bind, the addition of 32 kJ/mol of opening energy results in a shift to open probability of about 0.9 (Fig. 1c) . However, if we mutate one of the GABA sites to make its binding much weaker, an experiment performed by Baumann et al. [20] , then our model correctly predicts that, in comparison to normal receptors, mutant channels will activate only about 4-5% as efficiently (Fig. 1b) . Figure 2 depicts both etomidate and GABA as agonists, each with two equivalent sites. Etomidate's efficacy factor, d, was estimated to equal 0.008, corresponding to about 12 kJ/mol of gating energy. This is a lower efficacy than GABA, and when high etomidate is present, the addition of 24 kJ/mol of gating energy results in an open probability of about 0.3 (Fig. 2a) . The effect of a low concentration of etomidate alone (3 mM) is depicted in Fig. 2b . This concentration of etomidate elicits barely detectable channel activity in macrocurrent experiments, indicating an open probability around 0.005, or about 12 kJ/mol of gating energy. However, addition of high GABA concentrations still results in 32 kJ/ mol of additional binding energy, pushing the open probability of receptors close to 1.0 (Fig. 2c) . The presence of a low concentration of etomidate also means that even low [GABA] will result in detectable channel activation -thus the leftward shift in GABA concentration responses (Fig. 2d) .
MUTANT RECEPTOR PHENOTYPES USING AN MONOD-WYMAN-CHANGEUX ALLOSTERIC FRAMEWORK
The MWC allosteric model enables the quantitative analysis of the effects of GABA A receptor mutations within a consistent mechanistic framework. For example, a number of GABA A receptor mutations result in spontaneous channel activation in the absence of agonists [19, 21] . Traditional linear binding-gating mechanisms, which adequately describe the function of wild-type a1b2g2L receptors, assume that agonist must bind before channels open. In essence, these mechanisms assume that an infinite energy barrier exists between closed and open states when agonist is absent. As a result, spontaneously gating mutant receptors such as a1L264Tb2g2L [15] cannot be described using this mechanism. In the framework of MWC allosteric mechanisms, spontaneous gating is associated with a low L 0 value. In the case of a1L264Tb2g2L receptors, which display about 10% spontaneous activity, L 0 %9. The five parameters in Eq. (6) comprise the 'phenotype' of a GABA A receptor as assessed by how GABA and etomidate affect its gating [22] . As noted above, the L 0 parameter is intrinsic to the receptor and describes spontaneous gating. Experimentally, this is estimated using inhibitors like picrotoxin, which block spontaneously active channels [19, 23] . Once L 0 is known, GABA concentration-response data can be used to estimate K G and c, using least squares regression to Eq. (4) [15] . Similarly, values for K E and d can be estimated by fitting concentration-response data for etomidate direct activation to Eq. (5) [15] . Data where combinations of etomidate and GABA are present together can be added and used in a global fit to Eq. (6) [24] . However, the data must first be normalized to an absolute open probability scale of 0 to 1.0. This is done by explicitly adding back spontaneous activity to baseline-adjusted data and rescaling to estimated maximal GABA efficacy. Maximal GABA efficacy is estimated by adding strong positive modulators such as alphaxalone to maximal GABA [24] . Assuming that the maximal response to high GABA plus increasing [alphaxalone] results in an open probability near 1.0, one can back-calculate open probability in the presence of high GABA alone. We have recently described these methods in detail [25 & ]. If all other parameters remain unchanged, a pure 'binding' phenotype for an etomidate site mutation would alter K E without altering any other parameters in the model. Experimentally, this would appear as a change in the midpoint (EC 50 ) of the etomidate direct activation response curve, without a change in its magnitude. A pure 'efficacy' phenotype for an etomidate site mutation would alter the magnitude of etomidate direct activation. Both of these mutations would also alter the apparent interaction of etomidate with GABA.
INTERPRETING THE EFFECTS OF AN ETOMIDATE SITE MUTATION: a1M236W
Most often, mutations do not affect only a single aspect of drug-receptor interactions. The case of the a1M236Wb2g2L receptor illustrates this point [24] . Experimentally, this mutant receptor displays many differences in comparison to wild-type a1b2g2L receptors. The a1M236Wb2g2L receptors display spontaneous activation and increased sensitivity to GABA (Fig. 3) . They also display sensitivity to etomidate as a direct agonist, but modulation by a low concentration (3 mM) of etomidate is much weaker than that observed in wild-type receptors. Thus, based on descriptive analysis alone, it is not clear whether the a1M236W mutation increases or decreases etomidate binding or efficacy.
Analysis within the MWC model framework readily explains these changes and enables us to conclude that the a1M236W mutation actually reduces etomidate efficacy. First, the spontaneous activity of a1M236Wb2g2L receptor is about 15%, indicating a very low L 0 value near 6. This translates into about 22 kJ/mol of gating energy (Fig. 3a) . Because these receptors have a high propensity to open, addition of very little GABA or etomidate gating energy is needed to activate more receptors. This explains the apparently increased sensitivity to either agonist ( Fig. 3b and c) . In addition, the small degree of GABA modulation by 3 mM etomidate indicates reduced binding or efficacy relative to wild-type. Quantitative analysis suggests that efficacy is in fact reduced -instead of high [etomidate] adding 24 kJ/mol of gating energy in wild-type receptors (Fig. 2a) , etomidate only adds 10-11 kJ/ mol of gating energy in the mutant receptors (Fig. 3c ), yet this is sufficient to open nearly all channels. Thus, the overall MWC phenotype readily explains the observations that etomidate is a potent and efficacious direct agonist, but produces only a small 'left shift' in a1M236Wb2g2L receptors (Fig. 3d) .
CONCLUSION
The use of quantitative mechanistic models is an important advance over descriptive data analysis. We introduced an MWC allosteric co-agonist model for etomidate actions at its major molecular target [15] , and are using this model as an interpretive framework to better understand how GABA A receptor mutations [24, 26] affect interactions with this anesthetic. To date, the MWC co-agonist model has proven robust -we have not yet encountered a mutation that disobeys the underlying assumptions of the mechanism. The model also provides a framework for designing experiments to explore the etomidate-binding sites in more detail. Furthermore, we have recently found that propofol actions at GABA A receptors are consistent with a similar MWC model, and the data indicate that more than two propofol sites may exist on each GABA A receptor [27 Although the underlying concepts and mathematical formalism of MWC allosteric models can take considerable time to understand, some of these ideas are readily understood and illustrated as elements that shift the energy balance between open and closed states, resulting in a measurable shift in channel open probability.
